Zoetis (NYSE:ZTS – Get Free Report) had its price objective hoisted by analysts at Jefferies Financial Group from $83.00 to $85.00 in a report released on Friday. Jefferies Financial Group‘s price objective indicates a potential upside of 7.88% from the stock’s current price.
Other equities analysts have also issued reports about the stock. Cantor Fitzgerald set a $94.00 price objective on shares of Zoetis in a research report on Tuesday, August 25th. Zacks Research raised shares of Zoetis from a “strong sell” rating to a “hold” rating in a report on Monday, October 26th. Stifel Nicolaus decreased their price target on shares of Zoetis from $85.00 to $80.00 and set a “hold” rating on the stock in a research note on Thursday, August 20th. TD Cowen decreased their price target on shares of Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a research note on Tuesday, August 25th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a report on Friday, August 7th. Eight investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $101.25.
Read Our Latest Stock Report on Zoetis
Zoetis Stock Performance
Shares of Zoetis stock traded down $3.32 during trading on Friday, hitting $78.79. 1,993,844 shares of the stock were exchanged, compared to its average volume of 5,444,132. The stock has a market capitalization of $32.56 billion, a price-to-earnings ratio of 12.98, a price-to-earnings-growth ratio of 1.32 and a beta of 0.67. The company has a fifty day moving average price of $75.59 and a 200-day moving average price of $92.82. Zoetis has a 1-year low of $68.77 and a 1-year high of $132.49. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87.
Zoetis (NYSE:ZTS – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $1.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.51 by $0.24. The business had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. Zoetis’s revenue was down 1.3% on a year-over-year basis. During the same period last year, the business posted $1.70 EPS. As a group, equities analysts predict that Zoetis will post 6.15 EPS for the current fiscal year.
Institutional Investors Weigh In On Zoetis
A number of hedge funds and other institutional investors have recently modified their holdings of ZTS. Flossbach Von Storch SE purchased a new stake in Zoetis in the 2nd quarter valued at $302,601,000. BlackRock Inc. boosted its holdings in Zoetis by 10.8% during the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after acquiring an additional 3,845,869 shares during the last quarter. Ruane Cunniff & Goldfarb L.P. purchased a new position in Zoetis during the 1st quarter worth $286,660,000. Southpoint Capital Advisors LP grew its stake in shares of Zoetis by 340.0% in the 1st quarter. Southpoint Capital Advisors LP now owns 2,200,000 shares of the company’s stock worth $260,062,000 after acquiring an additional 1,700,000 shares in the last quarter. Finally, Carmignac Gestion bought a new stake in shares of Zoetis in the 2nd quarter worth $113,230,000. Institutional investors and hedge funds own 92.80% of the company’s stock.
Zoetis News Summary
Here are the key news stories impacting Zoetis this week:
- Positive Sentiment: Adjusted earnings were $1.75 per share, above the $1.51 consensus, and revenue of $2.39 billion topped estimates of $2.30 billion. Zoetis also raised its full-year 2026 profit outlook. Zoetis Lifts Annual Outlook While Braces For Cautious Pet Economy
- Positive Sentiment: Livestock revenue rose 7% to $797 million, helping offset weaker companion-animal product sales. Zoetis: 3 Key Takeaways for Long-Term Investors
- Neutral Sentiment: The company narrowed its full-year 2026 revenue guidance while raising its profit outlook, reflecting a stronger earnings outlook alongside a more measured sales picture. Zoetis Announces Third Quarter 2026 Results
- Negative Sentiment: Despite the quarterly beat, revenue declined 1.3% year over year and organic operational revenue fell about 1%. Zoetis also cautioned that pet owners are cutting back on veterinary visits, raising concerns about demand for companion-animal products and the 2027 outlook. Zoetis plans cautiously for 2027 as pet owners cut back on vet visits
About Zoetis
Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.
The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.
See Also
- Five stocks we like better than Zoetis
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
- Block by Block: Cash App Builds a Stronger Foundation
- Arista Networks Cashes In on the AI Infrastructure Buildout
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
